SynCore Biotechnology Co Ltd

SynCore Biotechnology Co., Ltd. develops and sells health foods, medicine inspection services, and biotechnology services in Taiwan. Its pipeline includes SB01, an injectable anti-cancer new chemical entity (NCE) in Phase II trials for head and neck cancer; SB02, an anti-cancer NCE in preclinical research for stomach cancer; SB03-Veregen, an ointment for external genital and perianal warts (EGW); SB04, a conventional drug in Phase II/III trials for dry age-related macular degeneration (AMD); and SB05-EndoTAG-1, a conventional drug in Phase III trials for pancreatic cancer and triple-negative breast cancer. The company also distributes epiCam cameras, including hand-held color, hand-held monochrome, and veterinary fundus cameras used to record the progression of ophthalmology diseases, as well as choroidal blood flow measurement. It has partnerships with Aresus, MacuCLEAR Inc., Y-YBAR, Epipole, Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes (NHRI). Incorporated in 2008 and headquartered in Yilan City, Taiwan, it operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.